<DOC>
	<DOC>NCT00262990</DOC>
	<brief_summary>The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.</brief_summary>
	<brief_title>Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>18 years of age or older Confirmed diagnosis of ovarian, fallopian or peritoneal cancer No more than three chemotherapy regimens Most recent regimen must have been platinum based Have an unresolved bowel obstruction Have had previous chemotherapy within 3 weeks Recovering from any surgery for any cause Other protocoldefined inclusion/exclusion criteria will apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Epithelial ovarian cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>primary cancer</keyword>
	<keyword>recurrent cancer</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>taxane chemotherapy</keyword>
	<keyword>platinum chemotherapy</keyword>
	<keyword>Patupilone</keyword>
	<keyword>taxane platinum resistant</keyword>
</DOC>